A phase 3 trial of DaiichiSankyo and Merck & Co.’s HER3-directed ... The trial compared the ADC patritumab deruxtecan to chemotherapy in people with metastatic or locally advanced EGFR-mutated ...
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by DaiichiSankyo (TSE: 4568) and being jointly developed ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.